Thiol-Functionalized Covalent Organic Frameworks as Thermal History Indictor for Temperature and Time History Monitoring

Various products, including foods and pharmaceuticals, are sensitive to temperature fluctuations. Thus, temperature monitoring during production, transportation, and storage is critical. Facile indicators are required to monitor temperature conditions via color changes in real time. This study aimed to prepare and apply thiol-functionalized covalent organic frameworks (COFs) as a novel indicator for monitoring thermal history and temperature abuse. The COFs underwent obvious color changes from bright yellow to purple after exposure to different temperatures for varying durations. The reaction kinetics are analyzed under isothermal conditions, which reveal that the order of reaction rates is k_−20°C < k_4°C < k_20°C < k_35°C < k_55°C. The activation energy (E_a) of the COFs is calculated using the Arrhenius equation as 50.71 kJ moL⁻¹. The COFs are capable of sensitive color changes and offer a broad temperature tracking range, thereby demonstrating their application potential for the monitoring of temperature and time exposure history during production, transportation, and storage. This excellent performance thermal history indicator also shows promise for expanding the application field of COFs.     

非线性系统鲁棒吸引的动态补偿方法

考虑非线性不确定系统的鲁棒吸引问题,借助于动态输出反馈,构造了两类控制律。这两类控制律分别可使相应的闭环系统被一任意小的区域鲁棒吸引,或被一预先设置的区域有限吸引。     

密码子优化的牛精蛋白基因在大肠杆菌中的表达

以PCR的方法得到牛精蛋白基因的基因，去其内含子，得到牛精蛋白cDNA，克隆入原核表达载体pGEX-2T中，组装成表达载体pGEX-2T-PE，利用大肠杆菌偏好的编码精氨酸的密码子CGT将野生型牛精蛋白基因中编码精氨酸的稀有密码子（AGA或AGG）替换掉，通过基因合成得到密码子优化的牛精蛋白的基因，将其克隆入原核表达载体pGEX-2T中，组装成表达载体pGEX-2T-PS。将这两个表达载体分别转化入大肠杆菌表达菌株BL21中，经IPTG诱导，同样条件下，野生型牛精蛋白基因无法得到表达，密码子优化的牛精蛋白基因能够得到良好的表达，表达产物约占细菌总蛋白的18％，将表达蛋白纯化，进行DNA－蛋白结合实验，发现其能与DNA发生非特异性的结合。     

6M32(51)氮氢气压缩机系统的技术改造

1 机组简介 6M32(51)-190/320-BX型氮氢气压缩机的基础件采用德国博尔格公司的专有技术,具体参数如下: 压缩介质:氮氢气,压缩级数:6级;转速:375rpm;行程:320mm,轴功率:2920kW,容积流量:190m~3/min;气量调节:回路调节,冷却填料润滑油:1.95 kg/h;重量:主机69.45t,     

国外几种脱硫醇工艺技术

硫醇是一种易挥发、有毒、腐蚀活性强的物质，在环保要求越来越严格的今天，必须将原油和凝析气中的硫醇加以脱除，才能达到环保要求。文章介绍了目前世界上采用的几种脱硫醇工艺。     

钢铁表面锌系磷化膜的研究

本文采用ＳＥＭ和ＴＥＭ等测试手段，研究了四功能处理液不同条件下在钢铁表面上形成锌系磷化膜的形貌，晶体结构；采用ＥＤＳ研究了磷化膜的化学成发，通过实验确定了Ｚｎ／Ｐ值在２．１２～３．２０时，磷化膜具有良好的耐蚀性。     

基于TMS320C32的CAN总线通信系统设计

为实现空间相机控制器与星务计算机之间的可靠数据通讯,设计了基于TMS320C32的CAN总线通信系统;针对TMS320C32和SJA1000的工作时序特点,利用可编程逻辑器件FPGA实现了接口逻辑转换,编写激励文件利用Modelsim软件进行了功能仿真,给出了CAN总线通信系统的软件设计,包括SJA1000的初始化、数据的发送接收及位定时参数的设定;最后通过周立功公司的ZLGCANTest软件对设计的CAN总线通信系统进行了测试;实验结果表明,系统的通信速率达到307.2kbps,通讯无误,满足相机控制器可靠性的要求。     

嵌入式预充电电源控制系统的设计与实现

研制了基于PC/104总线为核心的嵌入式预充电电源控制系统,重点阐述了该控制系统的硬件结构与软件设计;该控制系统以SBC-4680为控制系统主板,通过PC/104总线控制PCM-5120模拟量输入输出卡,控制PCM-5134的IO和定时计数卡,同时制作相应的接口电路及看门狗电路,在DOS操作系统中,利用C++编写底层软件,控制中采用PID算法及特殊数据处理方法,利用VB编写上位机操作界面与图形显示软件,实现与底层软件的以太网通信、信号的实时传输、显示与处理;实验证明,采用此预充电控制系统以后,使高压电源的波头质量得到极大提高,既消除了震荡,又避免了电压跌落等情况的出现,同时该电源的控制精度达到1%,因此,该控制系统完全满足电源控制及保护需要。     

An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer

Traditional endocrine therapy for prostate cancer (PCa) has been directed at suppression of the androgen receptor (AR) signaling axis since Huggins et al. discovered that diethylstilbestrol (DES; an estrogen) produced chemical castration and PCa tumor regression. Androgen deprivation therapy (ADT) still remains the first-line PCa therapy. Insufficiency of ADT over time leads to castration-resistant PCa (CRPC) in which the AR axis is still active, despite castrate levels of circulating androgens. Despite the approval and use of multiple generations of competitive AR antagonists (antiandrogens), antiandrogen resistance emerges rapidly in CRPC due to several mechanisms, mostly converging in the AR axis. Recent evidence from multiple groups have defined noncompetitive or noncanonical direct binding sites on AR that can be targeted to inhibit the AR axis. This review discusses new developments in the PCa treatment paradigm that includes the next-generation molecules to noncanonical sites, proteolysis targeting chimera (PROTAC), or noncanonical N-terminal domain (NTD)-binding of selective AR degraders (SARDs). A few lead compounds targeting each of these novel noncanonical sites or with SARD activity are discussed. Many of these ligands are still in preclinical development, and a few early clinical leads have emerged, but successful late-stage clinical data are still lacking. The breadth and diversity of targets provide hope that optimized noncanonical inhibitors and/or SARDs will be able to overcome antiandrogen-resistant CRPC.